After revolutionizing the weight-loss drug market, Novo ... disease and chronic kidney disease, compared with a placebo. Novo Nordisk’s chief rival, Eli Lilly, also released new heart health ...

which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. Novo Nordisk also gets rights to the ...

Novo Nordisk’sNOVO.B-0.63%decrease; red down pointing triangle once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks ... cardiovascular disease and/or chronic ...

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new data from a late-stage study of the GLP-1 receptor agonist. The phase 3 ...

The Food and Drug Administration approved Novo ... events such as heart attacks and strokes. Novo Nordisk is also studying ...

Novo Nordisk on Saturday said its diabetes pill ... become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death ...

Novo Nordisk’s attempt to gain an approval to ... the risk of cardiovascular events in adults with established heart disease who are obese or overweight. A heart failure nod was expected to ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes ... Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio ...

Novo Nordisk’s NVO NONOF obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition. What Happened ...